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Since Liraglutide, a fatty acid modified glucagon like peptide -1 (GLP1) analog, is still 
administered parenterally, this work aims at designing and optimizating Liraglutide 
encapsulated in polymeric nanoparticles for oral administration implementing Quality by 
Design (QbD) concept from the early stage of development. 
Rish assessmnet based study was successfully conducted followed by selecting the crtical 
process parameters (CPPs) and crirtical material attributes (CMAs) with the highest risk to be 
further investigated applying screening design of experiment (DOE).  Plackett Burman DOE 
was sucessfully implemented to understand and evaluate the effect of CPPs and CMAs on the 
size, encapsulation effeciency, polydisperisity index and zeta potential of Liraglutide loaded 
polymeric NPs. The design space was established and the optimized formula was prepared 
and examined for physiochemical properties, compatibility, structural stability and in vitro 
relesae behaviour. 
This work presents the potential of implementing the QbD methodology when designing such 
a complex system to ensure high quality of the final product. 
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